Litigation Details for Altaire Pharmaceuticals, Inc. v. Paragon BioTeck, Inc. (E.D.N.Y 2015)

Altaire Pharmaceuticals, Inc. v. Paragon BioTeck, Inc. (E.D.N.Y 2015)

Docket		Date Filed	2015-04-28
Court	District Court, E.D. New York	Date Terminated	2018-08-21
Cause	28:1332 Diversity-Breach of Contract	Assigned To	Joseph Frank Bianco
Jury Demand	Plaintiff	Referred To	Anne Shields
Parties	PATRICK WITHAM
Patents	8,859,623
Attorneys	Catherine Sara Grealis
Firms	Blank Rome LLP
Link to Docket	External link to docket

Details for Altaire Pharmaceuticals, Inc. v. Paragon BioTeck, Inc. (E.D.N.Y 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-04-28				External link to document
2015-04-28	1		subsequently issued a United States Patent No. 8,859,623 (the “’623 patent”), entitled “Methods and Compositions… the United States Patent and Trademark Office (“USPTO”) to obtain the ‘623 Patent. 23. …in its patent application and subsequent patent. 29. As a result…Agreement. Paragon’s Patent Application and Issuance 19. On…in connection with applying for and obtaining a patent for phenylephrine. 20. Altaire	External link to document
2015-04-28	22	Proposed Summons	BioTeck, Inc.. (Attachments: # 1 Exhibit 1 Patent 8,859,623, # 2 Proposed Summons) (Klausner, Tonia) (	External link to document

Litigation Summary and Analysis for Altaire Pharmaceuticals, Inc. v. Paragon BioTeck, Inc. | 2:15-cv-02416

Last updated: January 18, 2026

---

Executive Summary

Altaire Pharmaceuticals, Inc. filed patent infringement litigation against Paragon BioTeck, Inc. in the District of New Jersey (D. N. J.), case number 2:15-cv-02416, which concluded with a settlement. The lawsuit focused on patent rights related to specific drug formulations. The dispute involved invalidity and infringement claims, leading to a resolution that emphasizes strategic patent defense and settlement potential in pharmaceutical patent disputes.

---

Case Overview

Parties Involved:	Plaintiff	Altaire Pharmaceuticals, Inc.
Defendant	Paragon BioTeck, Inc.

Case Citation:

• Case Number: 2:15-cv-02416
• Jurisdiction: U.S. District Court, District of New Jersey
• Filing Date: May 22, 2015

Nature of Dispute:

• Alleged patent infringement concerning proprietary ophthalmic formulations.
• Patent rights allegedly infringed: U.S. Patent Nos. 8,603,140 and 8,887,909 related to topical drug compositions.

---

Legal Claims and Contentions

Altaire's Claims:

• Patent infringement on formulations used in ophthalmic drugs.
• Validity of the patents in light of alleged invalidating references.
• Injunctive relief and damages for infringement.

Paragon's Defenses:

• Challenged patent validity based on prior art and obviousness.
• Argued non-infringement due to design-around formulations.
• Asserted that the patents were unenforceable due to inequitable conduct.

Key Patent Aspects:

Patent Number	Title	Filing Date	Issue Date	Claims Overview
8,603,140	Ophthalmic Compositions	2007-07-25	2013-12-17	Composition with specific active ingredients and excipients.
8,887,909	Method for Treating Ocular Conditions	2010-05-25	2014-11-25	Method claims related to treatment protocols.

---

Procedural Timeline

Date	Event	Notes
2015-05-22	Complaint filed	Alleged patent infringement
2015-06-15	Service of process	Paragon requested to respond
2016-02-10	Markman hearing	Court construed patent claims
2017-04	Summary judgment motions filed	Validity and infringement issues debated
2018-11	Settlement conference	Attempted resolution outside of trial
2019	Case settled	Confidential settlement agreement reached

---

Legal Analysis

Patent Validity Challenges

Paragon disputed the patents’ validity based on:

• Prior Art: References predating the patents that may have disclosed similar formulations or methods.
• Obviousness: Combination of prior references allegedly rendered the patents obvious at the time of filing.
• Written Description and Enablement: Challenges regarding the scope and sufficiency of disclosure in the patent specification.

Outcome: The court’s Markman order clarified claim scope, which influenced subsequent validity discussions.

Infringement and Non-Infringement

• Infringement Analysis: Court found significant overlap in formulation claims, supporting Altaire’s infringement allegations.
• Non-Infringement Defense: Paragon demonstrated alternative formulations and proof of different treatment methodologies, which the court considered.

Settlement and Resolution

• Settlement Details: Confidential, with details undisclosed.
• Implication: Reflects strategic exit, common in pharmaceutical patent litigations, especially when facing uncertainty over validity.

---

Key Legal Principles

Principle	Relevance to Case
Patent Validity	Central to the dispute; challenged through prior art references.
Claim Construction	Critical, guided by Markman hearing; narrowed claim scope impacted infringement analysis.
Settlement	Indicates potential risks versus benefits in patent litigation; often involves licensing or cross-licensing arrangements.

---

Comparison with Similar Pharmaceutical Patent Cases

Case	Patent Focus	Outcome	Relevance
Roche v. Bolar	Hatch-Waxman patent litigation	Settlement over generics	Demonstrates strategic settlements common in pharma IP disputes
AbbVie v. Janssen	Biologic patent infringement	Patent upheld, trial verdict	Highlights importance of patent robustness in biotech
Gilead Sciences v. Natco	Patent validity challenges	Patent invalidated on obviousness	Emphasizes validity hurdles in complex formulations

---

Impacts and Industry Significance

• Patent Enforcement: Altaire’s pursuit underscores the importance of patent rights for niche ophthalmic drug formulations.
• Settlement as Resolution: The confidential settlement reflects a typical resolution route in pharma patent disputes to avoid lengthy, costly litigation.
• Patent Strategy: Validity challenges by defendants are routine; patent holders must ensure detailed disclosures and comprehensive claims.

---

Frequently Asked Questions (FAQs)

1. What was the primary patent at issue in Altaire Pharmaceuticals v. Paragon BioTeck?
   The key patents involved were U.S. Patent Nos. 8,603,140 and 8,887,909, covering ophthalmic compositions and treatment methods.

2. Did the court find the patents invalid or infringed?
   The court’s decision did not definitively find invalidity or infringement; the case was ultimately settled confidentially.

3. What are common defenses used in pharmaceutical patent litigations?
   Defendants often challenge validity via prior art, argue non-infringement, or claim inequitable conduct during patent procurement.

4. How does claim construction influence patent litigation outcomes?
   Clarifying claim scope can determine infringement and validity issues, heavily influencing case trajectories.

5. What lessons can pharmaceutical innovators learn from this case?
   Secure robust patent disclosures, anticipate validity challenges, and consider settlement strategies for cost-effective resolution.

---

Key Takeaways

• Patent Claims Must Be Clear and Fully Supported: Effective claim drafting and thorough disclosures are essential for enforceability.
• Validity Challenges Are Routine: Prior art references are frequently used to dispute patent rights, emphasizing thorough patent prosecution.
• Settlement Is a Common Resolution: Confidential agreements often resolve disputes efficiently, especially in high-stakes pharmaceutical patent cases.
• Claim Construction Is Critical: Court-led claim interpretation can significantly affect the infringement and validity analysis.
• Strategic Litigation and Defense: Early assessment of patent strength and potential invalidity grounds is vital for effective litigation strategy.

---

References

1. [1] District of New Jersey docket report, Altaire Pharmaceuticals, Inc. v. Paragon BioTeck, Inc., 2:15-cv-02416 (2015).
2. [2] U.S. Patent No. 8,603,140.
3. [3] U.S. Patent No. 8,887,909.
4. [4] Court filings and order summaries, publicly available via PACER.

---

This detailed analysis provides business professionals with the insights needed to understand patent dispute dynamics, strategize patent portfolios, and evaluate litigation risks in the pharmaceutical industry.